S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

BMY Bristol Myers Squibb Co

44.245

0.305 (0.69%)

Last Updated: 01:24:06

Delayed by 15 minutes

Bristol is one of the worst performing biopharmas this year. Will 2022 be different?

To read the full story on Seeking Alpha, click here.

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Bristol Myers Squibb Charts.

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Bristol Myers Squibb Charts.

Bristol Myers Squibb Co News

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Wednesday 1 May 2024 (4 hours ago) • GlobeNewswire Inc.

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Monday 29 April 2024 (2 days ago) • PR Newswire (US)

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Friday 26 April 2024 (5 days ago) • Business Wire

U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast
Thursday 25 April 2024 (6 days ago) • IH Market News

Bristol Myers Squibb Reports First Quarter Financial Results for 2024
Thursday 25 April 2024 (6 days ago) • Business Wire

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
Tuesday 23 April 2024 (1 week ago) • IH Market News

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
Monday 22 April 2024 (1 week ago) • Business Wire

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Tuesday 9 April 2024 (3 weeks ago) • Business Wire

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Sunday 7 April 2024 (4 weeks ago) • Business Wire

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Saturday 6 April 2024 (4 weeks ago) • Business Wire

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Wednesday 3 April 2024 (4 weeks ago) • Business Wire

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Tuesday 2 April 2024 (4 weeks ago) • Business Wire

More Bristol Myers Squibb Co News Articles

AUD vs US Dollar

Verizon Communications

Australian SE All Ordina...

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions